Clinical care of osteosarcoma (OSA) in dogs has seen little change during the past 2 decades, relying on amputation and platinum-based chemotherapy for pain control and survival. Recent advancements offer hope for improved outcomes. Genomic research reveals shared genetic abnormalities between canine and human OSA. Multidimensional imaging provides valuable staging and prognostic information. Limb-sparing approaches including stereotactic body radiation therapy are routine. Ablative therapies such as microwave ablation and histotripsy show promise. Immunotherapy including cell therapy and immune checkpoint inhibition are available. Radiopharmaceuticals are tuned to target OSA cells directly. These innovations may enhance treatment and prognosis for dogs with OSA.

中文翻译：

---

骨肉瘤的最新进展

狗骨肉瘤 (OSA) 的临床护理在过去 20 年中几乎没有变化，依靠截肢和铂类化疗来控制疼痛和生存。最近的进展为改善结果带来了希望。基因组研究揭示了犬类和人类 OSA 之间共有的遗传异常。多维成像提供有价值的分期和预后信息。包括立体定向身体放射治疗在内的保肢方法是常规方法。微波消融和组织解剖等消融疗法显示出希望。免疫疗法包括细胞疗法和免疫检查点抑制。放射性药物被调整为直接靶向 OSA 细胞。这些创新可能会增强患有 OSA 的狗的治疗和预后。